All four mutations cause the CMT2B neuropathy independently and dominantly in heterozygote patients, which has led to a focus on identifying a putative gain-of-function effect of the disease mutants (Spinosa et al., 2008; McCray et al., 2010; Cogli et al., 2013; Zhang et al., 2013). This evidence concerns the gene RAB7A and neuropathy.